MedTrace Logo

Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients

NCT06375473 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2026-01-06

No results posted yet for this study

Summary

This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.

Conditions

Interventions

DRUG

Irinotecan liposome II combination therapy regimen

Irinotecan liposome II combination therapy regimen

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Taiping Zhang, doctor · Peking Union Medical College Hospital, Beijing, China

  • Liwei Wang, doctor · Renji Hospital, Shanghai, China

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-19
Primary Completion
2027-04-19
Completion
2027-04-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06375473 on ClinicalTrials.gov